Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal cenegermin for acute NAION
NL-OMON61545Phase 2Not yet recruiting
- Sponsor
- Dompé
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-arteritic anterior ischemic optic neuropathy (NAION) comparing Intranasal cenegermin with Vehicle control (2 arms). Primary endpoint: Improvement in best corrected visual acuity responder rate. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
cenegermin
03
Conditions
non-arteritic anterior ischemic optic neuropathy (NAION)
Beyond the preview
Go deeper on NL-OMON61545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61545.